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ABSTRACT
Bovine respiratory syncytial virus (BRSV) causes
pneumonia in young cattle. Modified-live-virus (MLV) and
inactivated vaccines are currently used for the control of clinical
effects of BRSV infections in cattle. On the present research, the
stimulation of specific anti-BRSV immunoglobulin isotypes was
investigated, through the use of different commercially available
adjuvants (Water-in-oil emulsion, Quil A, Aluminum-
hydroxide) in inbred mice (Balb/C and C57BL/6). BRSV
antibodies were measured using an enzyme-linked
immunosorbent assay (ELISA) and the results were compared
to the antibody levels induced by immunization of animals
using live-BRSV-virus. Water-in-oil emulsion and alum-
adjuvant preparations induced higher levels of IgG1
immunoglobulins, whereas Quil A favored the production of
IgG2 antibodies, this last being a more appropriate response
profile for the specific case of BRSV.  Not using adjuvants
resulted in poor levels of specific antibodies.  The isotype profile
of specific antibodies obtained varied greatly depending on
the adjuvants used. This information may be useful for the
formulation of more effective BRSV inactivated vaccines;
however, these findings have to be confirmed in cattle.
Key words: bovine respiratory syncytial virus, BRSV, adjuvants,
murine model, inactivated vaccines.
RESUMO
O vírus respiratório sincicial bovino (BRSV) causa
pneumonia em bovinos jovens. Vacinas de vírus vivo modificado
(MLV) e vacinas inativadas são atualmente utilizadas para o
controle dos efeitos clínicos de infecções pelo BRSV em bovinos.
No presente trabalho, investigou-se a estimulação dos isotipos
de imunoglobulinas específicas anti-BRSV, através da utilização
de diferentes adjuvantes disponíveis comercialmente (água em
óleo de emulsão, Quil A, hidróxido de alumínio) em
camundongos isogênicos (Balb/C e C57BL/6). Anticorpos
contra o BRSV foram medidos usando-se um ensaio
imunoenzimático (ELISA), e os resultados foram comparados
com os níveis de anticorpos induzidos pela imunização de
animais utilizando-se o BRSV vivo. As preparações em que se
empregou óleo mineral e alumínio como adjuvantes induziram
altos níveis de imunoglobulinas IgG1, enquanto QuilA
favoreceu a produção de anticorpos de classe IgG2, sendo este
último um perfil de resposta mais desejável para o caso
específico de BRSV. A não utilização de adjuvantes resultou
em baixa produção de anticorpos específicos. O perfil de isotipos
de imunoglobulinas secretados variou bastante conforme o
adjuvante utilizado. Esta informação pode ser útil futuramente
na formulação de vacinas inativadas mais eficazes contra o
BRSV. Todavia, esses achados devem ser confirmados em
bovinos.
Palavras-chave: vírus respiratório sincicial bovino, BRSV,
adjuvantes, camundongos, modelos
murinos, vacinas inativadas.
INTRODUCTION
Bovine respiratory syncytial virus (BRSV),
a member of the Paramyxoviridae family, is  the major
cause of pneumonia in young cattle. Vaccines have
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been used at least for the last 30 years to control BRSV
infections in cattle (KERKHOFS et al., 2004; LETELLIER
et al., 2008) and nowadays there are a number of
commercially available BRSV vaccines (ELLIS et al.,
1995; HÄGGLUND et al., 2004); whose use is
controversial since its efficacy and potential
enhancement of disease in vaccinated animals are not
well documented under field conditions (SCHREIBER
et al., 2000; LARSEN et al., 2001). Experimental assays
using Modified-life virus (MLV) or inactivated vaccines
(ELLIS et al., 1995, 2005) showed different degrees of
protection against pulmonary pathology induced by
the challenge as well as production of neutralizing and
non-neutralizing antibodies to BRSV, on the
dependence of the type of vaccine and adjuvant used
(ELLIS et al., 2001, 2005). On the other hand, animals
vaccinated using BRSV inactivated virus, produced
high levels of total anti-BRSV IgG antibodies and lower
titres of BRSV-neutralizing antibodies (ELLIS et al.,
1995, 2005; PATEL & DIDLICK, 2004; MAWHINNEY
& BURROWS, 2005). Another important issue regarding
the use of BRSV-inactivated vaccines is the shift of the
immune response to the stimulation of T helper 2 (Th2)
immune responses (KALINA et al., 2004; GERSHWIN
et al., 2005; GERSHWIN, 2007). This was well
demonstrated in humans and cattle vaccinated using
formalin-inactivated vaccines (WEST et al., 1999;
KALINA et al., 2004). The efficacy of any virus-
inactivated vaccine relies on the use of appropriate
virus inactivation methods and use of adequate
adjuvant (COX & COULTER, 1997). The choice of the
adjuvant have to follow well defined parameters: I)
induction of specific antibodies; II) stimulation of
cellular immune responses, which are often lower using
inactivated vaccines, III) appropriate immunomodulation
(Th1/Th2 balance), avoiding side effects and
exacerbation of the disease on post-vaccination
challenged animals; iv) tolerability of the hosts to the
components of the adjuvant.
On the present  research,  it was investigated
the stimulation of specific anti-BRSV antibody
isotypes, through the use of different commonly used
commercial adjuvants in inbred mice. BRSV antibodies
were measured using an in-house enzyme-linked
immunosorbent assay (ELISA) and the results were
compared to the IgG isotypes induced by immunization
of mice using live-BRSV-virus. Two mice lineages were
used, based on its different levels of BRSV infection
resistance (SPILKI et al., 2006a).
MATERIALS   AND   METHODS
Brazilian BRSV isolate BRSV-25-BR was
used for the preparation of inactivated vaccines and
for the ELISA antigen production. CRIB cells, a clone
of Madin-Darby Bovine Kidney (MDBK) cells resistant
to the infection with BVDV (FLORES & DONIS, 1995),
which is susceptible to the infection with BRSV
(FLORES & DONIS, 1995; SPILKI et al., 2006a) were
used throughout. Cells were cultivated in Eagle’s
minimal essential medium (E-MEM) supplemented with
10% Fetal calf serum (FCS), free of antibiotics, following
routine protocols. Viral titres were calculated according
to Spearmann and Kärber method and expressed as
the log10 tissue culture infectious doses per 50µL
(TCID50 50µL-1).
Twenty-four hours after seeding of the cells
in 150cm2 bottles, E-MEM was removed and bottles
infected with 105.5 TCID50 50µL-1 of the BRSV-25-BR
isolate. Bottles were left one hour for adsorption at
37ºC. After, bottles were replenished with 50mL of E-
MEM without FCS and incubated for 72 hours at 37ºC,
when cytopathic effect was evident in about 90% of
the monolayers. Bottles were then vigorously shaken
to remove attached cells and stored at 4ºC for 24 hours.
The virus-cells mixture was centrifuged (5000 x g, 10
minutes); the pellet was then discarded and the
infectious titre of the bulk suspension was determined
(106.0 TCID50 50uL-1). Viral suspension was inactivated
with 0.01M binary ethylenimine (BEI) and applied
directly in the virus suspensions (previously heated at
37°C). The mixture was left at 37°C, and the inactivation
was stopped after 18 hours with sodium thiosulfate.
Inactivation was tested by inoculation of the viral
suspension in cell cultures and three blind passages
were performed to ensure that no infectious virus was
present on the suspensions. The vaccines were then
prepared using different adjuvants: water-in-oil type
emulsion (W/O), Quil A saponin (), Aluminum hydroxide
(Al2(OH)3), or no adjuvant (N/A). All adjuvants were
commercially purchased and kindly provided by
Laboratório Biovet S/A (Vargem Grande Paulista, SP,
Brazil). Non-adjuvanted vaccines were also prepared using
live-BRSV-virus (LV; infectious titre 106.0 TCID50 50uL-1).
Adjuvants were stirred with the inactivated virus
suspensions for 30min at 8°C and experimental vaccine
batches stored at 8°C until use, one week later.
For animal vaccination, thirty-six Balb/C
(haplotype: H-2d) and thirty-six C57BL6 (H-2b) mice,
which presented different levels of pulmonary
pathology after BRSV inoculation (SPILKI et al., 2006b)
were used on the present experiment. Eight week old
specific-pathogen-free mice males, were purchased
from CEMIB (Multidisciplinary Centre for Biological
Investigation, at UNICAMP). Animals were divided into
five groups (n=6, each) per mice lineage, into separate
cages. Another sixth group (n=6) was mock vaccinated
(C-) using the supernatant of non-infected CRIB cells.
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Animals were  acclimatized for 12 days before the
immunization and maintained with food and water ad
libitum throughout. Each virus inactivated vaccine,
live-BRSV-virus or mock-prepared vaccine was
administered subcutaneously (100µL per animal,
containing approximately 106.0 TCID50 viral particles)
on 0 days post-vaccination (DPV). Animals were re-
vaccinated on 30DPV. Blood samples were collected
by caudal vein puncture on days 0, 30, 60 and 90DPV
and after separation and aliquoting of the serum; all
the sera were stored at -20°C until use. At 90DPV,
animals were deeply anesthetized using a combination
of xylazine (Rompun, Bayer) and ketamine (Vetanarcol,
König), and exsanguinated through the jugular vein.
For measurement of anti-BRSV-specific
antibodies, BRSV antigen was prepared, as following.
Cell culture flasks (150cm2) infected the BRSV-25-BR at
a multiplicity of infection of1 and left 1h for adsorption
at 37°C. After adsorption, 50mL E-MEM left at 37°C
until CPE was evident in about 60% of the monolayer,
when the medium was removed and cells overlayed
with  0.2% OGP (n-octyl-ß-d-glucopyranoside) in
phosphate buffered saline (NaCl 8.5g, Na2HPO4.2H2O
1.55g, NaH2PO4.H2O 0.23g, distilled water qsp 1000mL,
pH 7.2), for 2 h at 4°C. Next, the cells were scraped off
the flasks, mixed with the supernatant and centrifuged
at 1500 x g to remove cell debris. The crude antigen
obtained was aliquoted and stored at -70°C until use.
The variables within the test were optimized previously
(antigen concentration, test serum and secondary
antibody dilutions, and reduction of background
noise), testing pooled and individual control positive
and negative mice sera obtained earlier from animals
immunized using completed Freund’s adjuvants. ELISA
plates were coated with an appropriate dilution of the
antigen (1:100, the optimal dilution as determined by
checkerboard titration) in bicarbonate buffer overnight
at 4°C. After adsorption of the antigen, plates were
washed once with 100µL of PBST-20 (0.5% Tween 20 in
PBS),  filled with another 100µL of PBST-20  and left to
stand for  1h at room temperature. The pooled mice
sera from each time point collected from the different
groups were diluted 1:2 in PBST-20 and added to
duplicate wells. After 1 h incubation at 37°C, the plates
were washed three times with PBST-20. Following
washing, anti-mouse whole IgG or to each selected
IgG isotype specific/ peroxidase conjugate (Bethyl
Laboratories, Montgomery TX, USA) was added as
secondary antibody (diluted 1:1000). Plates were
incubated for another hour at 37°C. After, three
washings with PBST-20 were done, 100µL of the
substrate 3,3’,5,5’-tetramethylbenzidine (TMB, Sigma)
were added and plates allowed to react at room
temperature for 30 minutes. The reaction was stopped
by the addition of 50µL of 0.5N H2SO4. The optical
densities (OD) were determined at 450nm in a Labsystem
Multiskan Bichromatic (Titertek) ELISA reader.
Statistical analyses were performed through
the analysis of variance (ANOVA), comparing each
group to another group of same mice lineage and the
corresponding to the opposite mice lineage, and to the
mock-vaccinated control values. The least significant
difference for P<0.05 was determined. Statistical
analysis was performed with Bioestat 5.0 (AYRES et
al., 2005).
RESULTS
Curves of measured specific anti-BRSV
antibody isotypes measured by ELISA are depicted in
figure 1. Water-in-oil (W/O) adjuvant gave the higher
levels of anti-BRSV specific antibodies for both Balb/
C and C57BL/6 mice, followed by Quil A and Aluminum
hydroxide Al2(OH)3. Statistical analysis showed that
levels of BRSV-specific IgG induced by W/O were
significantly higher (P<0.05) than those obtained for
all other treatments used, including Live-virus (LV).
No significant differences were observed for W/O
induced IgG responses between the two mice lineages
(P=0.6362). The results for Quil A in both Balb/C and
C57BL/6 mice were better than those obtained for
Al2(OH)3  and LV; Quil A gave higher levels of IgG
antibodies to BRSV in Balb/C mice (P=0.0193). Al2(OH)3
showed moderately higher levels of anti-BRSV IgG
antibodies in both inbred mice lineages when compared
to N/A and C- treatments; however, there was no
difference between Al2(OH)3 -adjuvanted vaccine and
LV in Balb/C mice (P=0.6624), differing from the situation
for C57BL/6 mice, were no differences between those
treatments may be found (P=0.002). Despite of this, no
differences were found comparing the Al2(OH)3 results
obtained for both mice lineages used (P=0.8302).
Results for LV were statistically significant different
from the N/A and C- groups, considering the samples
taken after re-vaccination, at 30 DPV.  It was also
observed that LV treatment induced higher levels of
BRSV-IgG antibodies in Balb/C than in C57BL/6 mice
(P=0.0143). Non-adjuvanted vaccinated mice didn’t
showstatistical differences from mock vaccinated
controls.
The isotype-specific IgG antibody titres
were determined by ELISA in the same samples, for the
days 0, 30 and 90 after immunization.  All isotypes were
detected for both inactivated adjuvanted vaccines and
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live virus, and no measurable responses were detected
for non-adjuvanted vaccine immunized mice. Both
Balb/C and C57BL/6 mice developed strong IgG1
responses after immunization with Al2(OH)3
adjuvanted BRSV-vaccine; other adjuvants also elicited
high levels of IgG1.
Balb/C mice presented higher levels of
IgG2a, IgG2b and IgG3 when compared to control
groups using Quil A, W/O or live virus, whereas C57BL/
6 mice showed weak IgG2a responses, with high levels
of IgG2b and IgG3. Al2(OH)3 induced low levels of
IgG2a and IgG2b in both mice lineages.
DISCUSSION
BRSV vaccine failure events are reported
both in scientific literature (SCHREIBER et al., 2000;
LARSEN et al., 2001) and clinical evidence are observed
by field veterinarians. On the present study, water-in-
mineral-oil emulsions (W/O), which is widely recognized
as a potent adjuvant for use in farm animals, showed
the best results when compared to any other treatments
used, and it was included on the present research to
serve as a “gold standard” for comparison with the other
treatments. However, its use have to be cautious since
Figure 1 - Levels of anti-BRSV IgG specific antibodies elicited by experimental inactivated vaccines, using
different adjuvants . Animals were re-vaccinated at day 30 DPV. The left graphs (A) describes the
levels of BRSV-specific IgG in Balb/C mice whereas right graph column, represents the levels of
BRSV specific isotypes in C57BL/6 mice. Values are expressed as percentual optical densities
(%OD).
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W/O may persist for long periods at the site of injection,
also being related with adverse reactions and
carcinogenicity (ROMERA et al., 2000).
Aluminum hydroxide elicited levels of  BRSV
antibodies in mice similar to those obtained when using
W/O or Quil-A as adjuvants. However, alum based
adjuvants are often associated to high levels of IgE
and Th2 like responses (WEST et al., 1999), which may
be deleterious for immunized animals, enhancing BRSV
disease after challenge (KALINA et al., 2004, 2006;
GERSHWIN et al., 2005; GRAYSON et al., 2007). In fact,
together with the modifications on epitopes related to
HRSV formalin-inactivated vaccines in children, leading
to exacerbation of pathology after challenge, these
vaccines were also alum-adjuvanted (KIM et al., 1969).
Good levels of Th1 and Th2 responses are
elicited by the use Quil A as an adjuvant (ELLIS et al.,
2005). The results obtained here and those previously
reported in the literature for the immunization using
BRSV-saponin-adjuvanted vaccines should be taken
with caution, since the results were obtained in a mice
model. If further confirmed in an experiment conducted
in cattle this may be considered as a proper choice for
the formulation of new BRSV-inactivated immunogens.
It is interesting that differences on the levels
of IgG antibodies to BRSV were found for Balb/C and
C57BL/6 mice when using both Quil A and Live-virus
vaccine preparations.  It can be hypothesized that this
may be an indirect effect from the differences on the
haplotypes of these mice lineages on the production
of certain isotypes (COX & COULTER, 1997). Detection
of IgE would be useful to analyze the Th2 deviation of
immune response; however, no significant differences
were observed for IgE secretion in Balb/C and C57BL/
6 mice (data not shown). This lack of evidence of
statistically significant differences may be an effect of
the time delayed between immunization and blood
collection and of the use of male mice throughout the
experiment, since gender differences were reported in
IgE responsiveness of mice,  which recently showed
to be controversial (CORTELING & TRIFILIEFF, 2004).
The present study showed that isotype
specific immune responses against inactivated BRSV
may be modulated in a mice model depending on the
adjuvants used; after confirmatory tests in cattle, this
approach may provide inactivated vaccine formulations
more effective against  BRSV infections. Studies using
challenge in cattle are also needed to ensure that the
humoral immune response modulation effect provided
by some adjuvants is related to clinical protection and
diminishing of virus shedding.
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